Tumour marker tests to support early detection and monitoring of prostate cancer
Elecsys® total PSA, a quantitative in vitro diagnostic test for determination of total (free + complexed) prostate specific antigen (tPSA) in human serum and plasma.
Prostate cancer is the second most common cancer in men and the leading death cause from cancer in men1. Early detection ensures timely management and treatment before prostate cancer can cause potentially fatal conditions2.
Screening approaches have reduced prostate cancer mortality in the USA and in Europe3,4,5. The most widely used screening tests for prostate cancer are digital rectal examination (DRE) in combination with serum total PSA6.
Guidelines recommend PSA screening in men at higher risk of developing prostate cancer, based on risk factors including age, family history and race7,8,9.
Total PSA can also be used to do active surveillance, assess therapy response and for post-treatment follow up10.
Elecsys® free PSA, a prostate specific antigen (free PSA) for the quantitative determination of free PSA in human serum and plasma.
Up to 80% of men with an elevated total PSA level of 4.0–10 ng/mL do not have prostate cancer11. In men with slightly elevated total PSA (3–10 ng/mL), free PSA helps to discriminate between benign conditions and prostate cancer, and reduces the number of unnecessary biopsies performed12,13,14.
Elecsys® total PSA and free PSA